{"id":"W4386704812","doi":"10.1161/jaha.122.029216","title":"Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial","year":2023,"lang":"en","type":"letter","venue":"Journal of the American Heart Association","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; Sanofi (Canada); University of Alberta; St. Michael's Hospital","funders":"Duke Clinical Research Institute; Esperion Therapeutics; Regeneron Pharmaceuticals; National Institutes of Health; HLS Therapeutics; Daiichi Sankyo Europe; Servier; Novo Nordisk; Daiichi-Sankyo; AstraZeneca; Amarin Corporation; St. Jude Medical; Boston Scientific Corporation; Pfizer; York University; Cleveland Clinic; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; Idorsia Pharmaceuticals; University of Toronto; Heart and Stroke Foundation of Canada; American Regent; Sanofi; Amgen","keywords":"Medicine; Tolerability; Placebo; Alirocumab; Family medicine; Gerontology; Internal medicine; Alternative medicine; Adverse effect","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004691828,0.0004078845,0.001552919,0.0001460977,0.0004635787,0.001099555,0.0004088692,0.002408825,0.002956065],"category_scores_gemma":[0.007446184,0.0002404972,0.001048444,0.0003942677,0.0004413046,0.0007425761,0.0003901104,0.002651354,0.0008029473],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007754235,"about_ca_system_score_gemma":0.001004009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002442108,"about_ca_topic_score_gemma":0.007572627,"domain_scores_codex":[0.9976854,0.001606826,0.0001478065,0.0001949175,0.0001864691,0.0001784441],"domain_scores_gemma":[0.995681,0.002363981,0.0007512587,0.000263783,0.0003241963,0.000615785],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5636441,0.002452696,0.09860088,0.001101912,0.003962723,0.002243099,0.0005135804,0.001228886,0.003788418,0.001371865,0.1782434,0.1428485],"study_design_scores_gemma":[0.4422483,0.02290779,0.3935114,0.001197201,0.0085864,0.001351028,0.0006419323,0.008063165,0.003135446,0.005651481,0.112317,0.0003888292],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8158851,0.02687478,0.001121377,0.1191064,0.004839466,0.0004028804,0.01055175,0.0001534272,0.02106488],"genre_scores_gemma":[0.9225115,0.003527416,0.000774753,0.05896105,0.003725687,0.0004445618,0.002454463,0.00004497256,0.007555616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004691828,"threshold_uncertainty_score":0.02481306,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1755256015901356,"score_gpt":0.4121072504405691,"score_spread":0.2365816488504335,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}